Pacific Biosciences of California (NASDAQ:PACB) — Stock Price
Pacific Biosciences of California (NASDAQ:PACB) is currently trading at $1.15 USD, down 3.36% today. Over the past 52 weeks, shares have ranged between $1.12 and $2.67. This page tracks Pacific Biosciences of California's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Pacific Biosciences of California stock valuation.
Pacific Biosciences of California (PACB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Pacific Biosciences of California's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Pacific Biosciences of California Income Statement — Revenue, Profit & Earnings by Year
Pacific Biosciences of California's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $160.00 Million | $154.01 Million | $200.52 Million | $128.30 Million | $130.51 Million |
| Cost of Revenue | $109.33 Million | $116.73 Million | $147.74 Million | $79.27 Million | $71.65 Million |
| Gross Profit | $50.67 Million | $37.28 Million | $52.78 Million | $49.03 Million | $58.86 Million |
| Research & Development | $97.31 Million | $134.92 Million | $187.17 Million | $193.00 Million | $112.90 Million |
| SG&A | $141.49 Million | $175.02 Million | $168.82 Million | $160.85 Million | $124.12 Million |
| Total Operating Expenses | $608.24 Million | $511.60 Million | $387.25 Million | $356.23 Million | $269.30 Million |
| Operating Income | $-557.56 Million | $-474.31 Million | $-334.47 Million | $-307.20 Million | $-210.44 Million |
| EBITDA | $-34.20 Million | $-242.77 Million | $-271.12 Million | $-282.24 Million | $-250.76 Million |
| EBIT | $-539.10 Million | $-296.12 Million | $-303.82 Million | $-299.56 Million | $-262.34 Million |
| Interest Expense | $6.95 Million | $13.41 Million | $14.34 Million | $14.69 Million | $12.53 Million |
| Income Before Tax | $-546.06 Million | $-309.54 Million | $-318.16 Million | $-314.25 Million | $-274.87 Million |
| Income Tax Expense | $318.00K | $316.00K | $-11.42 Million | $-17.32 Million | $-93.65 Million |
| Net Income | $-546.38 Million | $-309.85 Million | $-306.74 Million | $-314.25 Million | $-181.22 Million |
Pacific Biosciences of California Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Pacific Biosciences of California's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $784.08 Million | $1.26 Billion | $1.75 Billion | $1.77 Billion | $2.01 Billion |
| Total Current Assets | $375.03 Million | $495.68 Million | $742.05 Million | $852.07 Million | $1.10 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $215.80 Million | $334.56 Million | $451.50 Million | $447.23 Million | $583.67 Million |
| Net Receivables | $35.45 Million | $27.52 Million | $36.62 Million | $18.79 Million | $24.24 Million |
| Inventory | $49.28 Million | $58.76 Million | $56.68 Million | $50.38 Million | $24.60 Million |
| Property, Plant & Equipment | — | — | — | $81.34 Million | $79.12 Million |
| Goodwill | $317.76 Million | $317.76 Million | $462.26 Million | $409.97 Million | $409.97 Million |
| Total Liabilities | $778.73 Million | $753.85 Million | $1.04 Billion | $1.20 Billion | $1.22 Billion |
| Total Current Liabilities | $54.42 Million | $66.30 Million | $95.03 Million | $263.33 Million | $71.71 Million |
| Long-term Debt | $645.38 Million | $647.49 Million | $892.24 Million | $896.68 Million | $896.07 Million |
| Net Debt | $695.75 Million | $617.06 Million | $754.02 Million | $623.39 Million | $494.63 Million |
| Total Stockholder Equity | $5.35 Million | $506.59 Million | $701.30 Million | $562.90 Million | $790.99 Million |
| Retained Earnings | $-2.70 Billion | $-2.15 Billion | $-1.84 Billion | $-1.53 Billion | $-1.22 Billion |
Pacific Biosciences of California Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Pacific Biosciences of California generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-111.21 Million | $-206.06 Million | $-266.55 Million | $-263.21 Million | $-111.18 Million |
| Capital Expenditures | $2.71 Million | $6.19 Million | $8.84 Million | $16.93 Million | $5.93 Million |
| Free Cash Flow | $-113.92 Million | $-212.25 Million | $-275.39 Million | $-280.14 Million | $-117.11 Million |
| Investing Cash Flow | $115.45 Million | $124.00 Million | $4.60 Million | $116.08 Million | $-678.53 Million |
| Financing Cash Flow | $3.43 Million | $-42.99 Million | $116.27 Million | $9.62 Million | $1.17 Billion |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $41.67 Million | $71.04 Million | $72.12 Million | $78.61 Million | $80.73 Million |
| Depreciation | $386.41 Million | $53.34 Million | $32.69 Million | $17.32 Million | $11.59 Million |
| Change in Cash | $7.67 Million | $-124.15 Million | $-145.18 Million | $-137.51 Million | $379.87 Million |
Pacific Biosciences of California Earnings History — EPS Actual vs. Analyst Estimates
Track Pacific Biosciences of California's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | -0.14 | — |
| May 07, 2026 | -0.12 | -0.13 | +7.69% |
| Feb 12, 2026 | -0.12 | -0.13 | +7.69% |
| Nov 05, 2025 | -0.12 | -0.16 | +25.00% |
| Aug 07, 2025 | -0.13 | -0.18 | +27.78% |
| May 08, 2025 | -0.15 | -0.19 | +21.05% |
| Feb 13, 2025 | -0.20 | -0.17 | -17.65% |
| Nov 07, 2024 | -0.17 | -0.21 | +19.05% |